Back to mobile site

bluebird bio (BLUE) is Fundamentally Overvalued - Cantor

June 15, 2018 10:13 AM EDT Send to a Friend
Cantor Fitzgerald maintains Underweight on bluebird bio (NASDAQ: BLUE) price target of $122.00.Analyst Elemer Piros comments (emphasis StreetInsider) "At the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login